100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44DK123849
Award Date
9/15/19
Completion Date
8/31/23
Dollars Obligated
$2M
Overview
Activity
8
Transactions
8
Subawards
Similar Awards
Federal Agency
National Institute of Diabetes and Digestive and Kidney Diseases
Awardee
Crosslife Technologies Inc. (LFE6DJ6KL4E5)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Carlsbad, CA 92008, USA
Update #1
Update #2
RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV
Posted 9/12/19
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV - RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV CROSSLIFE TECHNOLOGIES INC. PROJECT SUMMARY/ABSTRACT APPROXIMATELY 500 000 PEOPLE DIE EACH YEAR FROM HEPATITIS C-RELATED LIVER DISEASES [1]. THE HEPATITIS C VIRUS CAN CAUSE BOTH ACUTE AND CHRONIC HEPATITIS INFECTION [1-2]. OVER TIME, CHRONIC HEPATITIS C CAN CAUSE SERIOUS HEALTH PROBLEMS INCLUDING LIVER DAMAGE, LIVER FAILURE, AND EVEN LIVER CANCER. EARLY DETECTION CAN SAVE LIVES. IF THE ANTIBODY TEST IS REACTIVE, AN ADDITIONAL NUCLEIC ACIDS BASED (RNA) TEST IS NEEDED TO DETERMINE IF A PERSON IS CURRENTLY INFECTED WITH HEPATITIS C. IF THE RNA TEST IS POSITIVE, THIS MEANS A PERSON CURRENTLY HAS HEPATITIS C AND SHOULD TALK TO A DOCTOR AND TREATING THE DISEASE. THERE IS AN URGENT NEED FOR SENSITIVE AND SPECIFIC POINT-OF-CARE (POC) DIAGNOSTICS FOR HCV. NUCLEIC-ACID BASED POC TESTS HAVE THE POTENTIAL TO OFFER TIMELY, SENSITIVE AND ACCURATE DIAGNOSIS OF HCV FOR IMPARTING PROPER CARE AND TREATMENT - ESPECIALLY IN SETTINGS WITHOUT ROBUST CLINICAL LABORATORY SUPPORT. THE AVAILABILITY OF A POC ASSAY TO DISTINGUISH WHICH HCV SEROPOSITIVE PATIENTS ARE INFECTED AND ASCERTAIN WHETHER PATIENTS HAVE DEVELOPED A SUSTAINED VIROLOGIC RESPONSE (SVR) WILL MAKE IT POSSIBLE TO TREAT PATIENTS ON A GLOBAL BASIS IN THE CURRENT ERA OF HIGHLY EFFECTIVE PAN-GENOTYPIC HCV REGIMENS. THEREFORE, WE AIM TO DEVELOP A RAPID, MULTIPLEX TEST THAT DETECTS AND GENOTYPES ALL SIX GENOTYPES OF HCV AT THE POINT-OF-NEED IN 90%) AND SPECIFICITY (>90%) TO THE QRT-PCR DATA ON THE SAME SAMPLES. WE WILL ALSO CONDUCT A LARGE-SCALE VALIDATION AND OBTAIN WORLD HEALTH ORGANIZATION (WHO) EXPEDITED REVIEW APPROVAL AND RECOMMENDATION FOR PROCUREMENT ON OUR PRODUCT AND MARKET IT FIRST TO NON-GOVERNMENTAL ORGANIZATIONS (NGO) SUCH AS THE DOCTORS WITHOUT BORDERS OR THE GATES FOUNDATION. WE WILL OBTAIN USFDA 510 K CLEARANCE IN PHASE 3 IN ORDER TO MARKET OUR PRODUCT IN THE U.S.
$0
2/26/24
Not listed
RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV - RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV CROSSLIFE TECHNOLOGIES INC. PROJECT SUMMARY/ABSTRACT APPROXIMATELY 500 000 PEOPLE DIE EACH YEAR FROM HEPATITIS C-RELATED LIVER DISEASES [1]. THE HEPATITIS C VIRUS CAN CAUSE BOTH ACUTE AND CHRONIC HEPATITIS INFECTION [1-2]. OVER TIME, CHRONIC HEPATITIS C CAN CAUSE SERIOUS HEALTH PROBLEMS INCLUDING LIVER DAMAGE, LIVER FAILURE, AND EVEN LIVER CANCER. EARLY DETECTION CAN SAVE LIVES. IF THE ANTIBODY TEST IS REACTIVE, AN ADDITIONAL NUCLEIC ACIDS BASED (RNA) TEST IS NEEDED TO DETERMINE IF A PERSON IS CURRENTLY INFECTED WITH HEPATITIS C. IF THE RNA TEST IS POSITIVE, THIS MEANS A PERSON CURRENTLY HAS HEPATITIS C AND SHOULD TALK TO A DOCTOR AND TREATING THE DISEASE. THERE IS AN URGENT NEED FOR SENSITIVE AND SPECIFIC POINT-OF-CARE (POC) DIAGNOSTICS FOR HCV. NUCLEIC-ACID BASED POC TESTS HAVE THE POTENTIAL TO OFFER TIMELY, SENSITIVE AND ACCURATE DIAGNOSIS OF HCV FOR IMPARTING PROPER CARE AND TREATMENT - ESPECIALLY IN SETTINGS WITHOUT ROBUST CLINICAL LABORATORY SUPPORT. THE AVAILABILITY OF A POC ASSAY TO DISTINGUISH WHICH HCV SEROPOSITIVE PATIENTS ARE INFECTED AND ASCERTAIN WHETHER PATIENTS HAVE DEVELOPED A SUSTAINED VIROLOGIC RESPONSE (SVR) WILL MAKE IT POSSIBLE TO TREAT PATIENTS ON A GLOBAL BASIS IN THE CURRENT ERA OF HIGHLY EFFECTIVE PAN-GENOTYPIC HCV REGIMENS. THEREFORE, WE AIM TO DEVELOP A RAPID, MULTIPLEX TEST THAT DETECTS AND GENOTYPES ALL SIX GENOTYPES OF HCV AT THE POINT-OF-NEED IN 90%) AND SPECIFICITY (>90%) TO THE QRT-PCR DATA ON THE SAME SAMPLES. WE WILL ALSO CONDUCT A LARGE-SCALE VALIDATION AND OBTAIN WORLD HEALTH ORGANIZATION (WHO) EXPEDITED REVIEW APPROVAL AND RECOMMENDATION FOR PROCUREMENT ON OUR PRODUCT AND MARKET IT FIRST TO NON-GOVERNMENTAL ORGANIZATIONS (NGO) SUCH AS THE DOCTORS WITHOUT BORDERS OR THE GATES FOUNDATION. WE WILL OBTAIN USFDA 510 K CLEARANCE IN PHASE 3 IN ORDER TO MARKET OUR PRODUCT IN THE U.S.
$0
6/21/23
Not listed
RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV - RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV CROSSLIFE TECHNOLOGIES INC. PROJECT SUMMARY/ABSTRACT APPROXIMATELY 500 000 PEOPLE DIE EACH YEAR FROM HEPATITIS C-RELATED LIVER DISEASES [1]. THE HEPATITIS C VIRUS CAN CAUSE BOTH ACUTE AND CHRONIC HEPATITIS INFECTION [1-2]. OVER TIME, CHRONIC HEPATITIS C CAN CAUSE SERIOUS HEALTH PROBLEMS INCLUDING LIVER DAMAGE, LIVER FAILURE, AND EVEN LIVER CANCER. EARLY DETECTION CAN SAVE LIVES. IF THE ANTIBODY TEST IS REACTIVE, AN ADDITIONAL NUCLEIC ACIDS BASED (RNA) TEST IS NEEDED TO DETERMINE IF A PERSON IS CURRENTLY INFECTED WITH HEPATITIS C. IF THE RNA TEST IS POSITIVE, THIS MEANS A PERSON CURRENTLY HAS HEPATITIS C AND SHOULD TALK TO A DOCTOR AND TREATING THE DISEASE. THERE IS AN URGENT NEED FOR SENSITIVE AND SPECIFIC POINT-OF-CARE (POC) DIAGNOSTICS FOR HCV. NUCLEIC-ACID BASED POC TESTS HAVE THE POTENTIAL TO OFFER TIMELY, SENSITIVE AND ACCURATE DIAGNOSIS OF HCV FOR IMPARTING PROPER CARE AND TREATMENT - ESPECIALLY IN SETTINGS WITHOUT ROBUST CLINICAL LABORATORY SUPPORT. THE AVAILABILITY OF A POC ASSAY TO DISTINGUISH WHICH HCV SEROPOSITIVE PATIENTS ARE INFECTED AND ASCERTAIN WHETHER PATIENTS HAVE DEVELOPED A SUSTAINED VIROLOGIC RESPONSE (SVR) WILL MAKE IT POSSIBLE TO TREAT PATIENTS ON A GLOBAL BASIS IN THE CURRENT ERA OF HIGHLY EFFECTIVE PAN-GENOTYPIC HCV REGIMENS. THEREFORE, WE AIM TO DEVELOP A RAPID, MULTIPLEX TEST THAT DETECTS AND GENOTYPES ALL SIX GENOTYPES OF HCV AT THE POINT-OF-NEED IN 90%) AND SPECIFICITY (>90%) TO THE QRT-PCR DATA ON THE SAME SAMPLES. WE WILL ALSO CONDUCT A LARGE-SCALE VALIDATION AND OBTAIN WORLD HEALTH ORGANIZATION (WHO) EXPEDITED REVIEW APPROVAL AND RECOMMENDATION FOR PROCUREMENT ON OUR PRODUCT AND MARKET IT FIRST TO NON-GOVERNMENTAL ORGANIZATIONS (NGO) SUCH AS THE DOCTORS WITHOUT BORDERS OR THE GATES FOUNDATION. WE WILL OBTAIN USFDA 510 K CLEARANCE IN PHASE 3 IN ORDER TO MARKET OUR PRODUCT IN THE U.S.
$0
6/21/23
Not listed
RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV - RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV CROSSLIFE TECHNOLOGIES INC. PROJECT SUMMARY/ABSTRACT APPROXIMATELY 500 000 PEOPLE DIE EACH YEAR FROM HEPATITIS C-RELATED LIVER DISEASES [1]. THE HEPATITIS C VIRUS CAN CAUSE BOTH ACUTE AND CHRONIC HEPATITIS INFECTION [1-2]. OVER TIME, CHRONIC HEPATITIS C CAN CAUSE SERIOUS HEALTH PROBLEMS INCLUDING LIVER DAMAGE, LIVER FAILURE, AND EVEN LIVER CANCER. EARLY DETECTION CAN SAVE LIVES. IF THE ANTIBODY TEST IS REACTIVE, AN ADDITIONAL NUCLEIC ACIDS BASED (RNA) TEST IS NEEDED TO DETERMINE IF A PERSON IS CURRENTLY INFECTED WITH HEPATITIS C. IF THE RNA TEST IS POSITIVE, THIS MEANS A PERSON CURRENTLY HAS HEPATITIS C AND SHOULD TALK TO A DOCTOR AND TREATING THE DISEASE. THERE IS AN URGENT NEED FOR SENSITIVE AND SPECIFIC POINT-OF-CARE (POC) DIAGNOSTICS FOR HCV. NUCLEIC-ACID BASED POC TESTS HAVE THE POTENTIAL TO OFFER TIMELY, SENSITIVE AND ACCURATE DIAGNOSIS OF HCV FOR IMPARTING PROPER CARE AND TREATMENT - ESPECIALLY IN SETTINGS WITHOUT ROBUST CLINICAL LABORATORY SUPPORT. THE AVAILABILITY OF A POC ASSAY TO DISTINGUISH WHICH HCV SEROPOSITIVE PATIENTS ARE INFECTED AND ASCERTAIN WHETHER PATIENTS HAVE DEVELOPED A SUSTAINED VIROLOGIC RESPONSE (SVR) WILL MAKE IT POSSIBLE TO TREAT PATIENTS ON A GLOBAL BASIS IN THE CURRENT ERA OF HIGHLY EFFECTIVE PAN-GENOTYPIC HCV REGIMENS. THEREFORE, WE AIM TO DEVELOP A RAPID, MULTIPLEX TEST THAT DETECTS AND GENOTYPES ALL SIX GENOTYPES OF HCV AT THE POINT-OF-NEED IN 90%) AND SPECIFICITY (>90%) TO THE QRT-PCR DATA ON THE SAME SAMPLES. WE WILL ALSO CONDUCT A LARGE-SCALE VALIDATION AND OBTAIN WORLD HEALTH ORGANIZATION (WHO) EXPEDITED REVIEW APPROVAL AND RECOMMENDATION FOR PROCUREMENT ON OUR PRODUCT AND MARKET IT FIRST TO NON-GOVERNMENTAL ORGANIZATIONS (NGO) SUCH AS THE DOCTORS WITHOUT BORDERS OR THE GATES FOUNDATION. WE WILL OBTAIN USFDA 510 K CLEARANCE IN PHASE 3 IN ORDER TO MARKET OUR PRODUCT IN THE U.S.
$0
9/21/22
Not listed
RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV - RAPID, POINT-OF-CARE NUCLEIC ACID TEST FOR HCV CROSSLIFE TECHNOLOGIES INC. PROJECT SUMMARY/ABSTRACT APPROXIMATELY 500 000 PEOPLE DIE EACH YEAR FROM HEPATITIS C-RELATED LIVER DISEASES [1]. THE HEPATITIS C VIRUS CAN CAUSE BOTH ACUTE AND CHRONIC HEPATITIS INFECTION [1-2]. OVER TIME, CHRONIC HEPATITIS C CAN CAUSE SERIOUS HEALTH PROBLEMS INCLUDING LIVER DAMAGE, LIVER FAILURE, AND EVEN LIVER CANCER. EARLY DETECTION CAN SAVE LIVES. IF THE ANTIBODY TEST IS REACTIVE, AN ADDITIONAL NUCLEIC ACIDS BASED (RNA) TEST IS NEEDED TO DETERMINE IF A PERSON IS CURRENTLY INFECTED WITH HEPATITIS C. IF THE RNA TEST IS POSITIVE, THIS MEANS A PERSON CURRENTLY HAS HEPATITIS C AND SHOULD TALK TO A DOCTOR AND TREATING THE DISEASE. THERE IS AN URGENT NEED FOR SENSITIVE AND SPECIFIC POINT-OF-CARE (POC) DIAGNOSTICS FOR HCV. NUCLEIC-ACID BASED POC TESTS HAVE THE POTENTIAL TO OFFER TIMELY, SENSITIVE AND ACCURATE DIAGNOSIS OF HCV FOR IMPARTING PROPER CARE AND TREATMENT - ESPECIALLY IN SETTINGS WITHOUT ROBUST CLINICAL LABORATORY SUPPORT. THE AVAILABILITY OF A POC ASSAY TO DISTINGUISH WHICH HCV SEROPOSITIVE PATIENTS ARE INFECTED AND ASCERTAIN WHETHER PATIENTS HAVE DEVELOPED A SUSTAINED VIROLOGIC RESPONSE (SVR) WILL MAKE IT POSSIBLE TO TREAT PATIENTS ON A GLOBAL BASIS IN THE CURRENT ERA OF HIGHLY EFFECTIVE PAN-GENOTYPIC HCV REGIMENS. THEREFORE, WE AIM TO DEVELOP A RAPID, MULTIPLEX TEST THAT DETECTS AND GENOTYPES ALL SIX GENOTYPES OF HCV AT THE POINT-OF-NEED IN 90%) AND SPECIFICITY (>90%) TO THE QRT-PCR DATA ON THE SAME SAMPLES. WE WILL ALSO CONDUCT A LARGE-SCALE VALIDATION AND OBTAIN WORLD HEALTH ORGANIZATION (WHO) EXPEDITED REVIEW APPROVAL AND RECOMMENDATION FOR PROCUREMENT ON OUR PRODUCT AND MARKET IT FIRST TO NON-GOVERNMENTAL ORGANIZATIONS (NGO) SUCH AS THE DOCTORS WITHOUT BORDERS OR THE GATES FOUNDATION. WE WILL OBTAIN USFDA 510 K CLEARANCE IN PHASE 3 IN ORDER TO MARKET OUR PRODUCT IN THE U.S.
$0
9/21/22